Episode 187 - June 26, 2026

What It Covers

Biotech Hangout Episode 187 covers the XBI rally from 130 to 155-160, AbbVie's $10.9B Apogee acquisition, China asset spin-out transactions including Sarafa and Olin Biosciences, FDA normalization under potential new commissioners, oncology investment challenges, and clinical data updates across HS, psychedelics, and androgenic alopecia.

Key Questions Answered

• •XBI Valuation Framework: Pharma free cash flow years-to-acquire all SMID-cap biotech sits at 3.7x in 2026, up from 3.5x in 2025 but well below the 5x+ peak of 2020. This metric provides a more grounded valuation anchor than EV-to-sales ratios for a sector where most companies generate no revenue, and current levels remain within a historically reasonable range despite the recent rally.
• •M&A vs. Independence Trade-off: RevMed rejected a rumored Merck offer near $120 per share (roughly 50% premium on an $80 stock) and subsequently reached $180, illustrating the cost of early exits. Boards should model the Vertex comparable — high revenue multiples sustained independently — before accepting acquisition premiums, particularly when the company holds a platform with multi-indication potential and strong commercial trajectory.
• •China Asset Valuation Context: The $136B headline figure for China out-licensing deals in 2025 is misleading; actual upfront payments totaled approximately $5.6B. Comparing that figure against a single acquisition like Apogee at $10.9B clarifies where value accrues. Non-China out-licensing activity has held steady at $140-160B annually since 2021, indicating China deal flow is additive rather than displacing US-originated innovation capital.
• •Order-of-Entry Pricing Power: AbbVie paid $10.9B for Apogee's IL-13 antibody Zumilock partly to position it as first-line biologic in atopic dermatitis before DUPIXENT biosimilars enter in 2031. Projected sales launch in 2030 means formulary positioning occurs while branded agents still lead. In heavily contracting-driven markets, arriving one year ahead of a biosimilar wave can justify multi-billion dollar premiums over cheaper, later-stage China-sourced alternatives.
• •FDA Normalization Signal: Multiple resubmissions — Regenexx Bio's Huntington gene therapy BLA, Replimune's oncolytic virus PDUFA date, and Moderna's flu vaccine — indicate the agency has returned toward standard evidence-based review. RBC Capital Markets identifies six commissioner candidates including Heidi Overton, John Crowley, and Richard Pops, with Vinay Prasad absent from the list, suggesting the regulatory environment is unlikely to revert to the restrictive posture seen in 2025.
• •Psychedelic Psychiatry Momentum: Definiium reported positive Phase 3 data for LSD in major depressive disorder, showing a robust efficacy signal with acceptable tolerability. Psychiatry residency programs, historically difficult to fill, have become among the most competitive to enter, driven by the psychedelic therapy wave. Investors tracking interventional psychiatry should monitor MDD label expansion as the FDA's willingness to approve beyond treatment-resistant depression becomes the key regulatory question.